AstraZeneca Plc (NYSE: AZN ) on Monday reported a mix of clinical trial outcomes for its lung cancer treatments , achieving notable successes in two late-stage trials while discontinuing a third study due to missed primary endpoints.
Favorable Results For Targeted Therapies
In the SAFFRON Phase 3 study, the combination of Tagrisso and Orpathys delivered a clinically meaningful and statistically significant extension in both overall survival and progression-free survival (PFS) against standard platinum-based chemotherapy.
This trial focused on patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) who experienced disease progression after earlier Tagrisso therapy.
According to the data, these patients exhibited high MET amplification or overexpression, a frequent resistance mechanism associated with a poor prognosis .
Read Next MediaAstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus
AstraZeneca and Bristol Myers reportedly discuss a $400 billion merger as analyst assesses valuation, patent risks and regulatory hurdles.
3 min read Read this articleThe safety profile remained consistent with prior studies, and findings will be shared with global regulatory bodies.
Latest Private Market Opportunities Join 400,000+ InvestorsOrpathys is co-developed by AstraZeneca and HUTCHMED Ltd (NASDAQ: HCM ).
The DESTINY-Lung04 Phase 3 trial yielded encouraging results for Enhertu as a primary treatment for unresectable, locally advanced, or metastatic HER2-mutant non-squamous NSCLC.
The engineered antibody-drug conjugate, jointly developed with Daiichi Sankyo, demonstrated substantial PFS improvements over the global standard of care.
Discontinuation of eVOLVE-Lung02 Study
On Monday, AstraZeneca said it is halting the eVOLVE-Lung02 Phase 3 trial.
The study assessed volrustomig combined with chemotherapy as an initial therapy for metastatic NSCLC patients exhibiting PD-L1 expression below 50%.
Following a scheduled review, the Independent Data Monitoring Committee determined the combination would likely fall short of its dual primary endpoints in the PD-L1-negative patient cohort.
Consequently, the trial is ending, though no unexpected safety signals emerged.
Meanwhile, other Phase 3 volrustomig evaluations targeting mesothelioma, cervical cancer, and head and neck squamous cell carcinoma will proceed as scheduled.
AZN Stock Price Activity: AstraZeneca shares were up 0.20% at $156.76 during premarket trading on Monday, according to Benzinga Pro data .
Read Next MediaWhy Sandisk Bulls Think the Old Memory Boom-And-Bust Playbook Is Dead
Sandisk (SNDK) stock jumps nearly 6% premarket as analysts highlight multi-year AI demand, expanding margins, and major buyback plans.
4 min read Read this articlePhoto by Piotr Swat via Shutterstock
Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here .
Posted In: Trading Ideas Movers News General Biotech Health Care Large Cap